Table 1.

Patient characteristics

N (%)
Gender Male66 (55.46%)
 Female53 (44.54%)
Age
 <208 (6.72%)
 20–4038 (31.93%)
 40–6059 (49.58%)
 ≥6014 (11.76%)
 Median44
FAB
 M07 (5.88%)
 M129 (24.37%)
 M229 (24.37%)
 M34 (3.36%)
 M421 (17.65%)1 M4E
 M523 (19.33%)
 NA5 (4.2%)Includes 4 “AML non-M3,” 1 RAEB MDS
Cytogenetics
 Normal60 (50.42%)
 inv(16)10 (8.4%)
 t(8;21)11 (9.24%)
 t(15;17)3 (2.52%)
 t(v;11q23)2 (1.68%)
 del(5/7q)6 (5.04%)
 del(9q)2 (1.68%)
 Complex4 (3.36%)
 tri 82 (1.68%)
 Other12 (10.08%)
 NA5 (4.2%)
Cytogenetic risk
 Favorable23 (19.33%)
 Intermediate76 (63.87%)
 Poor13 (10.92%)Includes 1 favorable + unfavorable
 NA6 (5.04%)Unavailable karyotype
CEBPA abnormalities
 Silenced6 (5.04%)
 Double mutation12 (10.08%)
 Single mutation1 (0.84%)
IDH mutation
IDH110 (8.4%)
IDH210 (8.4%)
Other alterations
NPM143 (36.13%)
FLT348 (40.34%)
DNMT3A27 (22.69%)
EVI1 overexpression8 (6.72%)
TET218 (15.13%)
  • Abbreviations: FAB, French-American-British acute myeloid leukemia classification; M4E, M4 with eosinophilia; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess blasts; tri 8, Trisomy 8.